Media, investors, advocacy organizations and others, please contact us here.
For US healthcare professionals only
The purpose of this Travere Therapeutics Medical Affairs website is to support healthcare professionals with scientific information. This website is also a channel for US healthcare professionals to submit questions or connect with Travere Therapeutics US healthcare professionals. The information provided is for educational purposes only and is not intended to promote any products. By continuing to use this site you are acknowledging that you are a US healthcare professional
Sparsentan, a Dual Endothelin Type A and Angiotensin II Subtype 1 Receptor Antagonist for the Treatment of Immunoglobulin A Nephropathy: Latest Trial Results, Pharmacokinetic Considerations, and Binding Profile
Efficacy and Safety of Sparsentan Versus Irbesartan in Patients with IgA Nephopathy (PROTECT): 2-year Results From a Randomised Active-Controlled Phase 3 Trial
Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgA immune complexes in a mouse model of IgA nephropathy
Kidney Failure Attributed to Focal Segmental Glomerulosclerosis: A USRDS Retrospective Cohort Study of Epidemiology, Treatment Modalities, and Economic Burden
Kidney Failure Attributed to Immunoglobulin A Nephropathy: A USRDS Retrospective Cohort Study of Epidemiology, Treatment Modalities, and Economic Burden
You are now leaving the Travere Therapeutics Medical Affairs website. The site you are accessing is maintained by a third party over whom Travere Therapeutics has no control. Travere Therapeutics does not review, approve, or necessarily endorse viewpoints, inferences, or conclusions stated in or implied by the content of this site. Travere Therapeutics is not responsible for third-party content or the consequences of your use thereof.
